Antidepressant-induced sexual dysfunction is becoming an increasingly common complaint amongst patients, particularly those treated with selective serotonin reuptake inhibitors. Many pharmacological interventions have been tried with some success, including Cyproheptadine, Amantadine, Yohimbine, Buspirone, and Amphetamine. However, persistent sexual dysfunction, despite these pharmacological interventions, remains a significant problem which can affect patient compliance and results in relapse and depression.

In an open trial, the effects using formulations of the extract of ginkgo biloba were studied. All patients have been involved in attempts to control sexual dysfunction through other pharmacological means including the use of Periactin, Yohimbine, Amantadine and/or Buspar. They were offered the option of continuing open trials of different medications or of using ginkgo biloba as an alternative to treat sexual dysfunction. All patients agreed to continue their antidepressant medication, and all met DSM IV criteria for a depressive disorder.